Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics

Current Medical Research and Opinion

Volumn 27, Issue 4, 2011, Pages 761-767

  Braunstahl, Gert Jan ^a   Leo, Jo ^b   Thirlwell, Jackie ^b   Peachey, Guy ^b   Maykut, Robert ^c  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Asthma management; Immunoglobulin E; Omalizumab

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; OMALIZUMAB; SHORT ACTING DRUG;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CHILD; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DATA ANALYSIS; DISEASE DURATION; DISEASE EXACERBATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERENNIAL RHINITIS; POSTMARKETING SURVEILLANCE; QUALITY OF LIFE; SCHOOL CHILD; UNCONTROLLED PERSISTENT ALLERGIC ASTHMA; URTICARIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CHILD; FEMALE; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; PROFESSIONAL PRACTICE; QUALITY OF LIFE; QUESTIONNAIRES; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT FAILURE; YOUNG ADULT;

EID: 79952692840     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.557717     Document Type: Article

References (18)

1. European Medicines Agency (EMEA): Omalizumab (Xolair®) summary of product characteristics (EU). Available at: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/Xolair/emea-combined-h606en.pdf (Accessed 28th August 2009)
2. Genentech Inc: Omalizumab (Xolair®) full prescribing information (US), July 2008. http://www.gene.com/gene/products/information/pdf/ xolairprescribing. pdf (Accessed 23 November 2009)
3. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-8 (Pubitemid 40293345)
4. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
5. Niven R, Chung KF, Panahloo Z, et al. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008;102:1371-8
6. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-97
7. Kulus M, Hebert J, Garcia E, et al. Omalizumab therapy reduces asthma exacerbations and is rated as effective by physicians in children with severe allergic (IgE-mediated) asthma. Clin Exp Allergy 2009a;39:1952 (abstract)
8. Kulus M, Hebert J, Garcia E, et al. The reduction in asthma exacerbations with omalizumab increases over time in children with severe allergic (IgE-mediated) asthma. Clin Exp Allergy 2009b;39:1953 (abstract)
9. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy 2004; 59:709-17 (Pubitemid 38850345)
10. Arts DGT, de Keizer NF, Scheffer G-J. Defining and improving data quality in medical registries: a literature review, case study, and generic framework. J Am Med Inform Assoc 2002;9:600-11 (Pubitemid 35231846)
11. Thomas M, Kay S, Pike J, et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J 2009;18:41-9
12. Juniper EF, Bousquet J, Abetz L, Bateman ED. GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006;100:616-21
13. Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994;47:81-7 (Pubitemid 24034293)
14. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64 (Pubitemid 11117589)
15. Cotes JE. Lung function; assessment and application in medicine, 5th edn. Oxford: Blackwell Scientific Publications, 1993
16. Korn S, Thielen A, Seyfried S, et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009;103:1725-31
17. Molimard M, de Blay F, Didier A, et al. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008;102:71-6 (Pubitemid 350161845)
18. Global Initiative for Asthma. Global strategy for asthma management and prevention. Issued January 1995 (NIH Publication No. 02-3659); updated 2002, 2003, 2004, 2005, 2006, 2007, 2008. Available at: www.ginasthma.org